影音先锋自拍偷拍为您找到"

eai045

"相关结果

EAI045 - InvivoChemhttps://www.invivochem.com/eai045EAI045 Related products InvivoChem Cat #: V2600; CAS #: 1942114-09-1 Description: EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI1045 has an IC50 of 3 nM against the L858R/T790M mutant with a 1000-fold selectivity over wild-type EGFR at 1 mM ATP. In combination with 10 μg/ml cetuximab, EAI045

EAI045 Related products InvivoChem Cat #: V2600; CAS #: 1942114-09-1 Description: EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI1045 has an IC50 of 3 nM against the L858R/T790M mutant with a 1000-fold selectivity over wild-type EGFR at 1 mM ATP. In combination with 10 μg/ml cetuximab, EAI045 …
www.invivochem.com/eai045

EAI045 | Allosteric EGFR L858R/T790M inhibitor | EAI 045 ...https://www.axonmedchem.com/product/2680EAI045 is an allosteric inhibitor that targets drug-resistant L858R/T790M-mutant EGFR tyrosine kinase (IC50 value of 3 nM), and spares the wild-type receptor (~1000-fold selectivity versus wild-type EGFR at 1 mM ATP).

EAI045 is an allosteric inhibitor that targets drug-resistant L858R/T790M-mutant EGFR tyrosine kinase (IC50 value of 3 nM), and spares the wild-type receptor (~1000-fold selectivity versus wild-type EGFR at 1 mM ATP).
www.axonmedchem.com/product/2680

EAI045, EGFR(T790M/C797S) inhibitor- MetonChemwww.metonchem.com/products/eai045-cas-naEAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S).

EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S).
www.metonchem.com/products/eai045-cas-na

Researchers find new way to inhibit mutant protein …https://www.dana-farber.org/newsroom/news-releases/2016/...When researchers combined the inhibitor, known as EAI045, with a second drug in mice with a form of lung cancer driven by mutant EGFR, the tumors shrank dramatically, even in mice whose tumors were resistant to every targeted therapy currently available.

When researchers combined the inhibitor, known as EAI045, with a second drug in mice with a form of lung cancer driven by mutant EGFR, the tumors shrank dramatically, even in mice whose tumors were resistant to every targeted therapy currently available.
www.dana-farber.org/newsroom/news-releases/2016/.....

EAI045 (CAS 1942114-09-1) | Cayman Chemicalhttps://www.caymanchem.com/product/19719In vivo, EAI045 induces tumor regression and reduces EGFR signaling in mice bearing EGFR L858R/T790M, EGFR Exon19del/T790M, and EGFR L858R/T790M/C797S tumors when administered at a dose of 60 mg/kg per day in combination with cetuximab.

In vivo, EAI045 induces tumor regression and reduces EGFR signaling in mice bearing EGFR L858R/T790M, EGFR Exon19del/T790M, and EGFR L858R/T790M/C797S tumors when administered at a dose of 60 mg/kg per day in combination with cetuximab.
www.caymanchem.com/product/19719

EAI045 - Selleckchem.comwww.selleckchem.com/products/eai045.htmlEAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
www.selleckchem.com/products/eai045.html

EAI045 - apexbt.comwww.apexbt.com/eai045.htmlEAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EGFR (epidermal growth factor receptor) is a cell-surface receptor tyrosine kinase. The receptor activation leads to dimerizati

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EGFR (epidermal growth factor receptor) is a cell-surface receptor tyrosine kinase. The receptor activation leads to dimerizati
www.apexbt.com/eai045.html

EAI045: The fourth-generation EGFR inhibitor overcoming ...https://www.sciencedirect.com/science/article/pii/S0304383516306863EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance Author links open overlay panel Shuhang Wang a Yongping Song b …

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance Author links open overlay panel Shuhang Wang a Yongping Song b …
www.sciencedirect.com/science/article/pii/S0304383...

EAI045|CAS 1942114-09-1 Buy EAI045 from supplier ...https://www.medchemexpress.com/EAI045.htmlEAI045 potently inhibits EGFR Y1173 phosphorylation in H1975 cells (EC 50 =2 nM), but not in HaCaT cells. EAI045 is an inhibitor of the L858R/T790M mutant with 1000-fold selectivity versus wild type EGFR at 1 mM ATP.10/10

EAI045 potently inhibits EGFR Y1173 phosphorylation in H1975 cells (EC 50 =2 nM), but not in HaCaT cells. EAI045 is an inhibitor of the L858R/T790M mutant with 1000-fold selectivity versus wild type EGFR at 1 mM ATP.
www.medchemexpress.com/EAI045.html

EAI045: The fourth-generation EGFR inhibitor …https://www.ncbi.nlm.nih.gov/pubmed/27840244Jan 28, 2017 · 1. Cancer Lett. 2017 Jan 28;385:51-54. doi: 10.1016/j.canlet.2016.11.008. Epub 2016 Nov 10. EAI045: The fourth-generation EGFR …

Jan 28, 2017 · 1. Cancer Lett. 2017 Jan 28;385:51-54. doi: 10.1016/j.canlet.2016.11.008. Epub 2016 Nov 10. EAI045: The fourth-generation EGFR …
www.ncbi.nlm.nih.gov/pubmed/27840244